Back to Authors

Tran, Nhan L.

https://orcid.org/0000-0003-0908-9964

A5016790638 | I1284308235

Mayo Clinic

Translational Genomics Research Institute

Citations 111

Abstract 3701: Fn14 overexpression in RCAS/tv-a rat gliomas promotes tumor progression, increases invasion and decreases survival

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 3701-3701

10.1158/1538-7445.am2019-3701

Abstract Fibroblast growth factor-inducible 14 (Fn14) is the cell surface receptor for the tumor necrosis factor (TNF) family member TNF-like weak inducer of apoptosis (TWEAK). The Fn14 gene is not normally expressed in healthy tissues, but expression is significantly increased in many primary solid tumor types, including glioblastoma (GBM). High Fn14 expression in tumors is often associated with the stimulation of cancer cell invasion leading to diffuse, aggressive tumors and metastasis. To investigate the effects of increased Fn14 expression in brain tumors, two different tumor types were developed using the RCAS/tv-a transgenic rat model: a low-Fn14, “proneural-like” (PDGFA/shP53 derived) tumor and a high-Fn14 (PDGFA/shP53/Fn14-derived) tumor. Interestingly, rats with high-Fn14 brain tumors had a significantly shorter median survival compared to those with low-Fn14 with 42 days and 70 days median survival, respectively. Using MR proton spectroscopy, both tumor types exhibited the markers of a malignant glioma such as increases in choline to creatinine ratio (Cho/Cr) and decreases in neuronal activity (NAA); however, high-Fn14 tumors also displayed an increase in lactate during tumor progression which is often a sign of high grade, necrotic tumors and poor prognosis. Morphologically, the two tumor subtypes appear quite different. H&E staining of the high-Fn14 tumors showed a highly malignant tumor with several areas of pseudopalisading necrosis within the tumor core. This is different than the somewhat more homogeneous morphology of the low-Fn14 proneural-like tumor. The pattern of tumor cell invasion also differs between the two brain cancer subtypes. High-Fn14 tumors show a more human GBM-like pattern by invading along the white matter tracts whereas low-Fn14 tumors appear to invade more locally with minimal white matter invasion. High-Fn14 tumors were positive for Fn14 throughout the tumor including the invasive rim of the tumor, which is also seen in human GBM, whereas the low-Fn14 tumor revealed very little staining even at the invasive rim. These findings indicate that increased Fn14 expression creates a more malignant brain tumors that develops and behaves more aggressively then low-Fn14 tumors. Citation Format: Nina Connolly, Heather Ames, Nhan L. Tran, Anthony Kim, Jeff Winkles, Graeme Woodworth. Fn14 overexpression in RCAS/tv-a rat gliomas promotes tumor progression, increases invasion and decreases survival [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3701.
MetaMarker: a pipeline for de novo discovery of novel metagenomic biomarkers

Bioinformatics | February 27, 2019 | Volume: 35 | Issue: 19 | Pages: 3812-3814

10.1093/bioinformatics/btz123 | PMID 30825371

Abstract Summary We present MetaMarker, a pipeline for discovering metagenomic biomarkers from whole-metagenome sequencing samples. Different from existing methods, MetaMarker is based on a de novo approach that does not require mapping raw reads to a reference database. We applied MetaMarker on whole-metagenome sequencing of colorectal cancer (CRC) stool samples from France to discover CRC specific metagenomic biomarkers. We showed robustness of the discovered biomarkers by validating in independent samples from Hong Kong, Austria, Germany and Denmark. We further demonstrated these biomarkers could be used to build a machine learning classifier for CRC prediction. Availability and implementation MetaMarker is freely available at https://bitbucket.org/mkoohim/metamarker under GPLv3 license. Supplementary information Supplementary data are available at Bioinformatics online.
CADD-48. microRNA-34a PACKAGED IN BACTERIAL NANOCELLS OVERCOMES THERAPEUTIC RESISTANCE IN GLIOBLASTOMA

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi282-vi282

10.1093/neuonc/noy148.1176

RDNA-06. A NOVEL ROLE OF SGEF IN MEDIATING GBM CELL SURVIVAL BY MODULATING THE DNA DAMAGE REPAIR MECHANISM

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi222-vi223

10.1093/neuonc/noy148.922

DRES-20. THE TNF RECEPTOR FAMILY MEMBER Fn14 IS HIGHLY EXPRESSED IN RECURRENT GLIOBLASTOMA (GBM) AND IN GBM PATIENT-DERIVED XENOGRAFTS WITH ACQUIRED TEMOZOLOMIDE RESISTANCE

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi79-vi80

10.1093/neuonc/noy148.327

CSIG-05. PI3K INHIBITORS PX-866 AND BEZ235 DIFFERENTIALLY MODULATE AUTOPHAGY IN GBM

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi43-vi44

10.1093/neuonc/noy148.171

DDIS-25. TARGETING GLIOBLASTOMA HETEROGENEITY WITH miR-34a

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi74-vi74

10.1093/neuonc/noy148.304

NIMG-12. RADIOGENOMICS ON VENUS AND MARS: IMPACT OF SEX-DIFFERENCES ON MRI AND GENETIC CORRELATIONS IN GLIOBLASTOMA

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi178-vi178

10.1093/neuonc/noy148.739

TMOD-18. THE PATIENT DERIVED XENOGRAFT NATIONAL RESOURCE: A COMPREHENSIVE COLLECTION OF HIGH-GRADE GLIOMA MODELS FOR PRE-CLINICAL AND TRANSLATIONAL STUDIES

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi272-vi272

10.1093/neuonc/noy148.1130

ANGI-02. A CRITICAL ROLE FOR LARG IN RhoC MEDIATED GLIOBLASTOMA CELL INVASION

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi28-vi28

10.1093/neuonc/noy148.104